WuXi AppTec

D3 Bio, established in 2020, is a biotechnology company headquartered in China. It specializes in the development and registration of innovative medicines, primarily focusing on oncology and immunology. The company's approach involves analyzing clinical and market data to identify gaps in current treatments, employing unique drug development methodologies to target new disease areas and routes, and ultimately providing patients with alternative therapeutic options.

Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on designing and developing novel oral therapeutics to treat chronic diseases with high unmet need. Utilizing advanced computational and structure-based technology, the company creates life-changing medicines by integrating cutting-edge advancements in computational chemistry and molecular interaction visualization. Its pipeline includes GSBR-1290, an oral glucagon-like-peptide-1 receptor agonist for type-2 diabetes mellitus and obesity, as well as ANPA-0073 and LTSE-2578 targeting pulmonary and cardiovascular diseases respectively. The company's team, with deep experience in complex biological targets and structure-based drug design, aims to deliver efficacious and safe treatments with broad commercial potential.

Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, and genetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients.

Megarobo is an AI and robotics company established in 2016 and headquartered in Beijing, China. It specializes in developing collaborative robots and advanced automation solutions tailored for life sciences, clinical diagnosis, and applied chemistry. By focusing on integrating robotics and artificial intelligence into industry applications, Megarobo aims to enhance research efficiency for life science companies and scientific research institutions. The company is dedicated to providing flexible and practical automation products that streamline laboratory services, ultimately driving innovation in the field of scientific research.

Engine Biosciences, established in 2014 and headquartered in Singapore, specializes in drug discovery and cellular reprogramming. The company's core offering is a validated platform that combines artificial intelligence and genetic perturbation to uncover gene interactions and biological networks. This platform enables researchers and drug developers to create targeted therapies and apply precision medicine. Engine Biosciences caters to prominent American corporations and research institutions, accelerating and reducing the costs of R&D for new medical therapies.

Oxford Genetics Ltd. is a UK-based synthetic biology company that focuses on DNA design, protein expression optimization, and cell line development technologies. Founded in 2011 and located in Begbroke, the company specializes in producing versatile cloning plasmids for research purposes in both academic and biotechnology institutions. Its product offerings include a wide range of plasmids, such as CRISPR plasmids, reporter genes, and various genetic tags, which are available for diverse research and production applications. The company ensures that all its products are free of intellectual property restrictions, facilitating broader access for researchers. Oxford Genetics distributes its products globally, reaching customers in numerous countries, and also offers online purchasing options. Additionally, the company maintains a strategic partnership with The Native Antigen Company Ltd.

AnchorDx is a biotechnology company specializing in next-generation sequencing techniques, particularly through the use of molecular liquid biopsies. This innovative approach allows for non-invasive access to genetic information, enabling patients to gain insights into their physiological conditions and better prepare for potential health issues. With a core team boasting over 20 years of experience in cancer genomics, genetics, and bioinformatics, AnchorDx aims to lead in precision medicine by developing comprehensive clinical applications and research platforms. The company fosters collaborations with various stakeholders, including hospitals, research institutes, and third-party testing agencies, to create a complete industrial chain that facilitates the transformation of academic research into clinical products. Through its commitment to developing independent intellectual property and competitive clinical testing solutions, AnchorDx provides accurate and comprehensive services to patients, healthcare providers, and medical institutions.

Drug Farm Inc. is a biotech company based in Shanghai, China, engaged in the development of innovative drugs and technologies for metabolic diseases such as obesity, diabetes, and fatty liver, as well as targeting innate immunity for conditions like HBV, cancer, and autoimmune diseases. The company employs its unique IDInVivo platform, which integrates advanced genetics and artificial intelligence to identify novel drug targets through genetic screens in living animals with intact immune systems. By leveraging various AI methodologies, including supervised learning, active learning, and reinforcement learning, Drug Farm aims to accelerate the medicinal chemistry development process, ultimately striving to deliver first-in-class therapeutic solutions to the healthcare industry.

D3 Bio, established in 2020, is a biotechnology company headquartered in China. It specializes in the development and registration of innovative medicines, primarily focusing on oncology and immunology. The company's approach involves analyzing clinical and market data to identify gaps in current treatments, employing unique drug development methodologies to target new disease areas and routes, and ultimately providing patients with alternative therapeutic options.

JW Therapeutics (Shanghai) Co., Ltd. is a biotechnology company based in Shanghai, China, specializing in the development, transformation, and promotion of cell-based immunotherapies. The company focuses on innovative therapies that utilize chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to enhance the body's immune response against cancer. JW Therapeutics is dedicated to creating transformative treatments for both hematological cancers and solid tumors, with its lead product candidate being relmacabtagene autoleucel, a CAR-T therapy targeting anti-CD19. By advancing these groundbreaking therapies, JW Therapeutics aims to improve survival rates and quality of life for cancer patients.

Insitro, Inc. is a data-driven company focused on drug discovery and development, particularly targeting nonalcoholic steatohepatitis (NASH). Founded in 2018 by Daphne Koller and based in South San Francisco, California, Insitro harnesses machine learning and high-throughput biology to revolutionize the process of drug discovery. The company creates extensive functional genomic data sets and integrates them with patient data through innovative machine learning techniques. This approach allows Insitro to build predictive models that enhance target selection, streamline the design of therapeutics, and optimize drug development strategies. By addressing critical challenges in pharmaceutical research and development, Insitro aims to accelerate the delivery of new and effective treatments to patients.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with an additional office in Conshohocken. Founded in 1999, the company focuses on the discovery and development of innovative T cell receptor-based therapeutics aimed at addressing significant unmet medical needs in cancer, viral diseases, and autoimmune diseases. Immunocore specializes in engineering T cell receptors (TCRs) and linking them to antibody fragments, which has led to the development of its lead product candidate, IMCgp100, currently undergoing clinical trials for metastatic melanoma. The company's proprietary TCR technology platform is validated and designed for efficient manufacturing, supporting both clinical and commercial supply. Immunocore was previously known as Avidex Limited before adopting its current name in 2008.

CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

Wisdo Health is an AI-powered social health platform focused on enhancing mental and physical well-being by fostering meaningful connections among users. The company offers an evidence-based peer support and benefits navigation platform that addresses the detrimental effects of social isolation and loneliness. By connecting individuals with shared experiences, Wisdo Health aims to improve health outcomes and reduce medical costs. The platform empowers users to learn from one another, facilitating personal growth and resilience in the face of life’s challenges and opportunities.

HuidaGene Therapeutics Co., Ltd., established in 2018, is a Shanghai-based biotechnology company specializing in the research and development of gene therapies for single-gene disorders and neurodegenerative diseases. The company employs its proprietary CRISPR-based, AI-driven HG-PRECISE platform to create potentially curative treatments. HuidaGene's clinical pipeline includes therapies for RPE65-associated retinal disease (HG004), neovascular age-related macular degeneration (nAMD) (HG202), MECP2 duplication syndrome (HG204), and Duchenne muscular dystrophy (DMD) (HG302). Additionally, the company has preclinical programs focused on therapies for amyotrophic lateral sclerosis (ALS) and Alzheimer's disease.

ViGeneron GmbH is a biotechnology company specializing in the development of gene therapies aimed at treating ophthalmic diseases, particularly those with significant unmet medical needs. Founded in 2017 and based in Starnberg, Germany, ViGeneron leverages two proprietary adeno-associated virus (AAV) technology platforms: the vgAAV gene therapy vector platform, which enhances transduction efficiency and allows for less invasive intravitreal treatment, and the REVeRT platform, designed to address diseases caused by mutations in large genes. The company is committed to advancing innovative therapies for retinal disorders and collaborates with leading biopharmaceutical companies to expand its impact in other disease areas. ViGeneron’s experienced team brings extensive expertise in AAV vector technology and clinical ophthalmic gene therapy programs.

Huimei Technology is a National high-tech enterprise that offers medical artificial intelligence solutions.

Pharmapace, Inc., founded in 2013 and based in San Diego, California, specializes in providing a comprehensive range of clinical research services tailored for biotechnology and pharmaceutical companies. The company offers expertise in clinical and statistical programming, data management, biostatistics, clinical data integration, project management, and medical writing. Pharmapace aims to deliver exceptional value by offering high-quality consulting and outsourcing services that support clients throughout all phases of clinical trials, including medical publications and safety evaluations. As a subsidiary of WuXi Clinical, Pharmapace focuses on aligning customized delivery solutions with the specific project goals and financial capabilities of its clients, thereby facilitating their drug development programs.

Arrakis Therapeutics, Inc. is a biopharmaceutical company based in Waltham, Massachusetts, that specializes in drug discovery focused on ribonucleic acid (RNA) targets. Established in 2015, the company utilizes a proprietary platform that combines advanced RNA bioinformatics, structural tools, and chemical libraries to identify new RNA targets and develop RNA-targeted small molecules (rSMs). This innovative approach aims to address various diseases, including cancer, neurological disorders, and rare genetic conditions. Arrakis also offers SHAPEware, a software tool designed to analyze and predict RNA secondary structures and potential ligand-binding sites, further enhancing its drug development capabilities. Through its comprehensive pipeline, Arrakis Therapeutics seeks to improve treatment options and outcomes for patients across multiple therapeutic areas.

PT HaloDoc is a digital healthcare platform based in Jakarta, Indonesia, established in 2016. The company connects patients with a network of 19,000 licensed doctors and 1,000 certified partner pharmacies through its innovative communication platform. Users can engage with medical professionals via video calls, voice calls, and chat, allowing for real-time consultations and health advice. Additionally, HaloDoc facilitates the ordering of laboratory tests that can be conducted at home, enhancing the convenience of accessing healthcare services. The platform aims to simplify and improve the healthcare experience for patients by providing easy connections to doctors, clinics, and hospitals, as well as offering medical delivery services through its partner pharmacies.

Schrödinger is a healthcare-focused software company that specializes in computational drug design, serving pharmaceutical and biotechnology research sectors. Established in 1990, it offers a powerful computational platform that aids biopharmaceutical and industrial companies, as well as academic and government institutions, in their research efforts globally. Schrödinger operates through two main segments: Software and Drug Discovery. The Software segment supplies solutions aimed at enhancing the drug discovery process across the life sciences and materials science industries. Meanwhile, the Drug Discovery segment generates revenue through a portfolio of preclinical and clinical programs, both independently and through collaborative efforts. The company is committed to advancing science and talent to support its platform and has over 400 employees, engaging with customers and collaborators in more than 70 countries.

Inspirna is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates that target essential drivers of cancer. Utilizing a discovery platform centered on RNA biology, Inspirna identifies novel cancer targets that contribute to tumor growth and disease progression. The company is advancing several first-in-class oral small molecules, including RGX-202, aimed at treating patients with RAS mutant colorectal cancer, and RGX-104, which is in development for small cell lung cancer and non-small cell lung cancer. Through its microRNA-based target discovery approach, Inspirna seeks to provide effective treatment options for cancer patients by employing targeted therapies that leverage small molecules and biologics.

Magnolia Neurosciences Corporation is a New York-based company focused on drug discovery and development, specifically targeting neuroprotective therapies for central nervous system diseases and neurodegeneration. Established in 2018, the company aims to create proprietary small molecule therapeutics that prevent neuronal cell death, offering new treatment options for patients with neurodegenerative disorders and related conditions. Magnolia Neurosciences was founded to advance technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium. Through its innovative approach, the company seeks to address significant medical needs in the field of neurology.

Verge Genomics is a biotechnology company focused on transforming drug discovery through the application of artificial intelligence. Founded by experts in machine learning and seasoned neuroscience drug developers, the company aims to leverage advancements in computational genomics and insights into neuroscience to discover innovative therapeutics for neurodegenerative diseases. Its drug discovery platform employs machine learning algorithms to analyze large datasets, identifying potential drug targets and predicting effective treatments. By accelerating the development of life-saving therapies, Verge Genomics seeks to enhance patient outcomes and reduce the costs associated with pharmaceutical development, thereby addressing critical challenges in the healthcare sector.

Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.

NuProbe is a genomics and molecular diagnostics company that develops a platform of reagents and genetic toehold probes for noninvasive nucleic acid profiling. Their Sample‑In Answer‑Out solution integrates cell‑free DNA extraction, qPCR, sequencing and bioinformatics to detect mutations, CNVs, gene fusions and low‑frequency variants with high sensitivity. Founded in 2016, the company operates from Cambridge, Massachusetts and Shanghai, China, and focuses on early detection of cancer and infectious diseases for clinical and research use.

Hua Medicine, established in 2009, is a Shanghai-based clinical-stage drug development company. It specializes in therapies for diabetes and central nervous system (CNS) disorders in China. The company's primary focus is Dorzagliatin, an oral drug for Type 2 diabetes, which is in Phase 3 clinical trials, both as a standalone treatment and in combination with metformin. Additionally, Hua Medicine is developing Dorzagliatin in combination with other drugs and mGLUR5 for Parkinson's disease levodopa-induced dyskinesia, both in pre-clinical stages. The company's mission is to address unmet medical needs in China through innovative drug development.

JW Therapeutics (Shanghai) Co., Ltd. is a biotechnology company based in Shanghai, China, specializing in the development, transformation, and promotion of cell-based immunotherapies. The company focuses on innovative therapies that utilize chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to enhance the body's immune response against cancer. JW Therapeutics is dedicated to creating transformative treatments for both hematological cancers and solid tumors, with its lead product candidate being relmacabtagene autoleucel, a CAR-T therapy targeting anti-CD19. By advancing these groundbreaking therapies, JW Therapeutics aims to improve survival rates and quality of life for cancer patients.

Engine Biosciences, established in 2014 and headquartered in Singapore, specializes in drug discovery and cellular reprogramming. The company's core offering is a validated platform that combines artificial intelligence and genetic perturbation to uncover gene interactions and biological networks. This platform enables researchers and drug developers to create targeted therapies and apply precision medicine. Engine Biosciences caters to prominent American corporations and research institutions, accelerating and reducing the costs of R&D for new medical therapies.

AnchorDx is a biotechnology company specializing in next-generation sequencing techniques, particularly through the use of molecular liquid biopsies. This innovative approach allows for non-invasive access to genetic information, enabling patients to gain insights into their physiological conditions and better prepare for potential health issues. With a core team boasting over 20 years of experience in cancer genomics, genetics, and bioinformatics, AnchorDx aims to lead in precision medicine by developing comprehensive clinical applications and research platforms. The company fosters collaborations with various stakeholders, including hospitals, research institutes, and third-party testing agencies, to create a complete industrial chain that facilitates the transformation of academic research into clinical products. Through its commitment to developing independent intellectual property and competitive clinical testing solutions, AnchorDx provides accurate and comprehensive services to patients, healthcare providers, and medical institutions.

ResearchPoint Global (RPG) is a global contract research organization offering comprehensive clinical trial services to pharmaceutical, medical device, and biotechnology companies. With operations in over 60 countries, RPG delivers a broad spectrum of services including project management, site selection and monitoring, safety and medical oversight, data management, biostatistics, and medical writing across all phases of clinical development, specializing in multi-regional trials.

Unity Biotechnology, Inc. is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing age-related diseases. The company specializes in clearing senescent cells through the creation of senolytic medicines, which specifically target vulnerabilities unique to these cells while sparing healthy ones. Its lead drug candidates include UBX0101, currently in Phase II clinical trials for musculoskeletal conditions like osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is developing treatments for various conditions related to aging, including pulmonary and neurological disorders, as well as kidney and liver diseases. Founded in 2009 and headquartered in South San Francisco, California, Unity Biotechnology was previously known as Forge, Inc. before changing its name in 2015.

Rodeo Therapeutics Corp. is a Seattle-based drug development company that focuses on creating novel small molecule therapies aimed at tissue repair and regeneration. Founded in 2017, the company targets specific biological pathways and enzyme mechanisms critical for healing. Its primary objectives include developing treatments for inflammatory bowel disease and enhancing blood cell reconstitution after bone marrow transplants. Rodeo's innovative approach involves increasing tissue levels of prostaglandin PGE2 by inhibiting the enzyme 15-PGDH, which has shown promise in protecting against colitis and promoting liver regeneration in various animal models. This research positions Rodeo Therapeutics to contribute significantly to the medical management of these conditions.

CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

Forerunner Medical (Shanghai) Co., Ltd., established in 2009, specializes in the development and manufacturing of innovative medical devices aimed at minimally invasive treatments. The company focuses on creating low-temperature plasma radio-frequency generators and electrodes specifically designed for sports medicine and tumor treatment. By leveraging extensive domestic clinical data and advanced technology, Forerunner Medical aims to meet both domestic and global healthcare needs. The organization emphasizes the quality and safety of its products, ensuring high performance, aesthetic appeal, and user convenience. Its commitment to excellence is reflected in its state-of-the-art production equipment and professional expertise, which contribute to its competitive advantage in the medical device industry.

HD Biosciences Inc. is a biotechnology company based in Shanghai, specializing in contract research for drug discovery. As a subsidiary of WuXi PharmaTech, it offers a comprehensive suite of services including assay development, high-throughput drug screening, structure-activity relationship analysis, and hit-to-lead biology solutions. The company has developed advanced technology platforms for drug discovery and has established long-term research agreements with major pharmaceutical clients, including Pfizer and Organon. HD Biosciences is recognized as a leader in biology-based drug discovery services in China, providing a range of capabilities from hit identification to in vivo pharmacology, thereby supporting the development of innovative pharmaceutical and biotechnology solutions.

ApoGen Biotechnologies, Inc. is a biotechnology company based in Seattle, Washington, established in 2014. The company specializes in developing innovative therapeutics aimed at addressing the challenges of drug resistance in cancer treatment. Recognizing that the mutation of cellular DNA is central to cancer progression, ApoGen focuses on therapies that target key drivers of genomic mutations and tumor evolution. By doing so, the company aims to slow or halt the ongoing mutations within cancer genomes, which are significant contributors to treatment failure, cancer recurrence, and metastasis. Through its advanced therapeutic approaches, ApoGen Biotechnologies seeks to improve outcomes for patients facing the complexities of cancer evolution and drug resistance.

Strateos specializes in automating chemistry, biology, and tissue analysis in closed-loop robotic labs, accelerating drug discovery programs for pharmaceutical partners. By combining advanced robotics, software for imaging and analytics, and remote cloud laboratories, Strateos enables more rapid and efficient discovery of new drug candidates. The company was formed through a merger of Transcriptic, which developed the first robotic cloud laboratory platform for life science research, and 3Scan, which specialized in automating tissue analysis. Strateos aims to express life science methods as data, enabling infrastructure virtualization and driving the next generation of discovery with significant time and cost efficiencies.

Unity Biotechnology, Inc. is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing age-related diseases. The company specializes in clearing senescent cells through the creation of senolytic medicines, which specifically target vulnerabilities unique to these cells while sparing healthy ones. Its lead drug candidates include UBX0101, currently in Phase II clinical trials for musculoskeletal conditions like osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is developing treatments for various conditions related to aging, including pulmonary and neurological disorders, as well as kidney and liver diseases. Founded in 2009 and headquartered in South San Francisco, California, Unity Biotechnology was previously known as Forge, Inc. before changing its name in 2015.

Crelux GmbH is a company specializing in X-ray crystallography and ultra-pure protein services, focused on advancing structure-based drug discovery. Founded in 2005 and headquartered in Planegg, Germany, the company offers a diverse portfolio that includes kinases, nuclear receptors, molecular chaperone systems, and proteases. Crelux provides tailored solutions in protein preparation, crystallization, and structure determination, primarily serving pharmaceutical, biotech, and research organizations. With a commitment to enhancing the efficiency and effectiveness of drug discovery projects, Crelux also emphasizes individualized support for its clients. It operates as a subsidiary of WuXi PharmaTech (Cayman) Inc., following a strategic partnership with 4SC Discovery GmbH.

Lodo Therapeutics Corporation is a drug discovery and development company dedicated to creating novel therapeutics derived from natural sources. It focuses on addressing significant health challenges, particularly resistant infectious diseases and cancers, by collaborating with global pharmaceutical companies and leading non-governmental organizations. Founded to realize the scientific vision of Dr. Sean Brady from Rockefeller University, Lodo Therapeutics utilizes a genome-based, culture-independent platform to discover and characterize small molecules sourced from environmental microbial DNA. This innovative approach leverages advancements in DNA sequencing and bioinformatics to explore the untapped potential of microbial evolution, aiming to identify therapeutically valuable pharmaceutical products. Headquartered in New York City at the Alexandria Center for Life Science, Lodo Therapeutics is committed to harnessing the power of nature in the fight against undruggable targets and high unmet medical needs.

Petra Pharma Corporation is a clinical-stage pharmaceutical company based in New York, focused on discovering and developing innovative therapies that modulate phosphoinositide (PI) signaling pathways for the treatment of cancer and metabolic diseases. Founded in 2015, the company targets novel enzyme pathways that play crucial roles in various cellular processes, such as cell division, growth, trafficking, and signaling. By developing small molecules aimed at these processes, Petra Pharma seeks to create impactful therapeutic options that enhance patient care and improve health outcomes.

DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.

TruTag Technologies, Inc. is a technology company specializing in precision-fabricated nano-porous silica for applications in drug delivery, product authentication, and data intelligence. The company has developed TruTag, an edible microtag aimed at identifying, authenticating, and ensuring the quality of medicines, medical products, food items, and consumer goods. This innovation helps mitigate issues such as counterfeiting, product diversions, and quality control, serving various industries including healthcare, life sciences, food and beverages, and electronics. TruTag Technologies operates a state-of-the-art manufacturing facility in Hawaii and has engineering offices in California, with additional business development offices across the United States and in Scotland. The company has garnered recognition for its technological advancements, including accolades from the SPIE Prism Awards and the Edison Awards, and has been acknowledged by the World Economic Forum as a Technology Pioneer.

WuXi NextCODE operates as a clinical diagnostics company specializing in sequence-based genomics. The firm provides a platform that assists physicians in obtaining critical clinical insights, enabling rapid and accurate diagnoses for patients. Its services include genome interpretation, data analysis, and data mining, along with security and data protection measures. The company also offers custom integration services and both clinical-grade and non-clinical-grade sequencing. With technology developed over 16 years at deCODE genetics, WuXi NextCODE aims to facilitate the integration of genomic data into patient care and diagnosis. Based in Cambridge, Massachusetts, the company was acquired by WuXi AppTec in 2015 and has since focused on addressing the challenges of genome interpretation and big data in healthcare.

ALDEA Pharmaceuticals, Inc. is a biotechnology company focused on developing small-molecule modulators of the aldehyde dehydrogenase (ALDH) enzyme superfamily. Founded in 2008 and headquartered in Redwood City, California, the company aims to address diseases associated with aldehyde metabolism dysfunction, which can range from acute alcohol toxicity to rare conditions such as Fanconi anemia. ALDEA's proprietary technology offers new product opportunities targeting a variety of therapeutic areas, including the development of ALDH activator compounds that enhance the detoxification of harmful aldehydes like acetaldehyde. These advancements are intended to alleviate acute symptoms and mitigate long-term tissue damage and cancer risk related to alcohol consumption and other toxic aldehyde-related diseases.

TruTag Technologies, Inc. is a technology company specializing in precision-fabricated nano-porous silica for applications in drug delivery, product authentication, and data intelligence. The company has developed TruTag, an edible microtag aimed at identifying, authenticating, and ensuring the quality of medicines, medical products, food items, and consumer goods. This innovation helps mitigate issues such as counterfeiting, product diversions, and quality control, serving various industries including healthcare, life sciences, food and beverages, and electronics. TruTag Technologies operates a state-of-the-art manufacturing facility in Hawaii and has engineering offices in California, with additional business development offices across the United States and in Scotland. The company has garnered recognition for its technological advancements, including accolades from the SPIE Prism Awards and the Edison Awards, and has been acknowledged by the World Economic Forum as a Technology Pioneer.

Avelas Biosciences is focused on advancing cancer surgery through innovative intraoperative imaging technology. The company has developed a proprietary platform that utilizes activatable cell-penetrating peptides to provide real-time diagnosis of metastatic nodes during surgical procedures. This technology enables oncologic surgeons to create a luminous map of the surgical area, improving their ability to identify and remove cancerous tissue effectively. By enhancing surgical precision, Avelas Biosciences aims to reduce the need for repeat surgeries and ultimately improve patient outcomes, establishing a new standard of care in oncological surgery.